Clinical Trials Logo

Clinical Trial Summary

GNE myopathy, an ultra-rare disease, is a severe progressive myopathy that typically presents in early adulthood as weakness in the distal muscles of the lower extremities and progresses proximally, leading to a loss of muscle strength and function, and ultimately a wheelchair-bound state. The rate of progression is gradual and variable over the course of 10-20 years or longer.

There is a need to understand the world wide epidemiology of this ultra-rare condition, better understand a long-term disease course and the progression of disease-specific features, support translational research by evaluating burden illness and support clinical research recruitment. Therefore, the study will longitudinally collect information via an online patient registry platform.


Clinical Trial Description

GNE myopathy is an ultra- rare condition. Most of the knowledge is coming from case reports or small cohort observations. There is a need to more precisely understand the long-term disease course and the progression of disease-specific features of GNE myopathy, and in turn characterise the overall burden of this illness. Also, to better understand the disease, describe it variability, genotype-phenotype correlation, quality of life, epidemiology, health-economics aspects and need for assistive walking devices. Collected data needs to be harmonised to be compatible collaborative work with Remudy (Japanese patient registry). This collaborative effort will enable the analysis of the largest GNE myopathy data set in the world. To this end, this study will collect patient information longitudinally. Upon patient's agreement, the registry curator can contact nominated clinicians to request additional data or data validation.

Study Objectives

The objectives of the study are to:

- Longitudinally characterize disease-specific features of GNE myopathy

- Characterize the burden of illness and quality of life in patients with GNE myopathy

- Support recruitment in research activities

- Inform registry participants via newsletters about scientific developments in the GNE myopathy field ;


Study Design


Related Conditions & MeSH terms


NCT number NCT04009226
Study type Observational [Patient Registry]
Source Newcastle University
Contact Registry Curator
Phone 0191 2418605
Email lucy.imber@newcastle.ac.uk
Status Recruiting
Phase
Start date March 2014
Completion date December 2021

See also
  Status Clinical Trial Phase
Recruiting NCT01417533 - A Natural History Study of Patients With GNE Myopathy and GNE-Related Diseases
Completed NCT01634750 - Phase I Clinical Trial of ManNAc in Patients With GNE Myopathy or Hereditary Inclusion Body Myopathy (HIBM) Phase 1
Completed NCT01517880 - A Phase 2 Study to Evaluate the Dose and Pharmacodynamic Efficacy of Sialic Acid-Extended Release (SA-ER) Tablets in Patients With GNE Myopathy or Hereditary Inclusion Body Myopathy Phase 2
Completed NCT02377921 - Phase 3 Randomized, Double-Blind, Placebo-Controlled Study to Evaluate Sialic Acid in Patients With Glucosamine (UDP-N-acetyl)-2-epimerase Myopathy (GNEM) or Hereditary Inclusion Body Myopathy (HIBM) Phase 3
Terminated NCT02736188 - Study to Evaluate the Safety and Efficacy of Aceneuramic Acid Extended-Release (Ace-ER) Tablets in Patients With Glucosamine (UDP-N-acetyl)-2-epimerase Myopathy (GNEM) or Hereditary Inclusion Body Myopathy (HIBM) Phase 3
Completed NCT01830972 - An Open Label Phase 2 Extension Study of Higher Dose Sialic Acid-Extended Release (SA-ER) Tablets and Sialic Acid-Immediate Release (SA-IR) Capsules in Patients With Glucosamine (UDP-N-acetyl)-2-Epimerase (GNE) Myopathy Phase 2
Completed NCT04671472 - Efficacy Confirmation Study of NPC-09 Phase 3
Completed NCT02346461 - An Open Label Phase 2 Study of ManNAc in Subjects With GNE Myopathy Phase 2
Active, not recruiting NCT04231266 - Multi-Center Study of ManNAc for GNE Myopathy Phase 2
Completed NCT01784679 - GNE-Myopathy Disease Monitoring Program (GNEM-DMP): A Registry and Prospective Observational Natural History Study to Assess GNE Myopathy or Hereditary Inclusion Body Myopathy (HIBM)
Terminated NCT02731690 - A Study to Evaluate the Safety of Aceneuramic Acid Extended Release (Ace-ER; UX001) Tablets in Glucosamine (UDP-N-acetyl)-2-Epimerase (GNE) Myopathy (GNEM) (Also Known as Hereditary Inclusion Body Myopathy [HIBM]) Patients With Severe Ambulatory Impairment Phase 2